Prostate cancer (PCa) is one of the most important medical problems facing the male population. The complex management of the different stages of PCa, the improvement of detection techniques, and the increasing variety of treatment options led to a growing interest in a multidisciplinary approach for the diagnosis and treatment of PCa over the last few years. An example of a multidisciplinary approach in PCa can be found in the treatment of newly diagnosed high-risk PCa for which the objectives of treatment are two-fold. There is a need for local tumour control, as well as a need for treatment of microscopic metastases likely to be present but undetectable until disease progression. Therefore, the optimal treatment approach in these patients should be multimodal, but the exact combinations and timing of the treatment is still a point of discussion.

We invite investigators to contribute original research articles as well as review articles that will stimulate the continuing efforts to understand the molecular pathways underlying high-risk PCa, the development of multimodal strategies to treat this condition, the development of reproducible methods to predict outcomes following treatment, and the evaluation of outcomes. We are particularly interested in articles describing the new modalities for clinical characterization of high-risk PCa, advances in molecular genetics and molecular diagnostics, new insights into the role of surgery, radiotherapy, hormonal therapy, and chemotherapy in the multimodal approach of the disease, and the future directions in diagnostics, outcome predictors, and novel treatment strategies of high-risk prostate cancer. Potential topics include, but are not limited to:

• Defining high-risk localized PCa
• Novel biomarkers in high-risk PCa: how to overcome the limitations of clinical risk classifications
• New imaging modalities in the local staging of high-risk localized PCa
• MRI in early detection of bone metastases
• The role of radical prostatectomy in the treatment of high-risk localized PCa
• The role of lymphadenectomy in high-risk PCa
• The role of adjuvant radiotherapy after surgery in high-risk PCa
• Combined radiotherapy and hormonal treatment in high-risk localized PCa
• Potential feasibility of surgery in very aggressive settings (salvage surgery in radiorecurrent PCa, in hormone refractory PCa, in PSA over 100,etc.)
• Is there a role for adjuvant hormonal therapy after surgery for high-risk PCa?
• Is there a role for chemotherapy in the primary management of high-risk localized PCa?

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/au/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable: